Q3 2025 Harvard Bioscience Inc Earnings Call Transcript
Key Points
- Harvard Bioscience Inc (HBIO) reported revenue of $20.6 million, at the high end of their guidance range, indicating strong financial performance.
- Gross margin improved to 58.4%, exceeding the guidance range and reflecting operational efficiency and a favorable product mix.
- The company achieved a sequential increase in adjusted EBITDA to $2 million, driven by reduced operating expenses.
- Harvard Bioscience Inc (HBIO) expanded its distribution agreement with Fisher Scientific, enhancing product visibility and access across North America.
- The launch of the Incubate MultiWell system has been well-received, with initial orders and shipments already completed, indicating strong market interest.
- Revenue for the third quarter was below the $22 million reported in the prior year's third quarter, indicating a year-over-year decline.
- Revenue in China decreased sequentially by 6.3% and year-over-year by 19.6%, reflecting challenges in the region.
- The ongoing U.S. government shutdown poses a risk to NIH funding distribution, potentially impacting future sales.
- Cellular and molecular sales in Europe decreased sequentially by 0.7% and year-over-year by 13%, indicating a decline in this product segment.
- Despite improvements, the company still faces challenges in achieving consistent year-over-year revenue growth across all regions.
Good day and Welcome to the third quarter 2025 Harvard Bioscience Earnings Conference call. All participants will be in listen-only mode. After todayĆ¢s presentation, there will be an opportunity to ask questions. To ask a question, please press star 11. If your question has been answered and you would like to remove yourself from the queue, please press star 11 again. Please note this event is being recorded. IĆ¢m now going to turn the conference over to Taylor Krawczyk, Senior Vice President at ELLIPSIS TA. Please go ahead.
Thank you, Operator, and good morning, everyone. Thank you for joining the Harvard Bioscience third quarter 2025 Earnings Conference call. Leading the call today will be John Duke, President and Chief Executive Officer, and Mark Frost, Interim Chief Financial Officer. In conjunction with todayĆ¢s recorded call, we have provided a presentation that will be referenced during our remarks that is posted to the Investor Relations section of our website at investor.harvardbioscience.com. Please
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investorsā 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
